Trichloroethylene risk assessment: A review and commentary

Critical Reviews in Toxicology

Volumn 39, Issue 9, 2009, Pages 782-797

  Jollow, David J ^a   Bruckner, James V ^b   McMillan, David C ^c   Fisher, Jeffrey W ^b   Hoel, David G ^a   Mohr, Lawrence C ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Carcinogenesis; PBPK modeling; Peroxisome proliferation; Presystemic elimination; Risk assessment; Trichloroethylene

Indexed keywords

ALCOHOL; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; CHLORAL HYDRATE; CYTOCHROME P450 2E1; DICHLOROACETIC ACID; DRINKING WATER; GLUCURONIDE; GLUTATHIONE TRANSFERASE; TRICHLOROETHYLENE;

BLADDER CANCER; CANCER RISK; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CLARA CELL; CYTOMEGALY; DOSE RESPONSE; DOSIMETRY; DRUG BINDING; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; GENOTOXICITY; HEALTH CARE POLICY; HUMAN; KIDNEY CANCER; KIDNEY CELL; LEYDIG CELL; LIVER CELL; LIVER METABOLISM; LIVER TUMOR; METABOLIC ACTIVATION; METABOLIC RATE; MOUSE STRAIN; NITROGEN DEPOSITION; NONHUMAN; POLLUTANT; PRACTICE GUIDELINE; RAT STRAIN; REVIEW; RISK ASSESSMENT; SERTOLI CELL; TOXICOKINETICS;

ANIMALS; ENVIRONMENTAL EXPOSURE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RISK ASSESSMENT; TRICHLOROETHYLENE; WATER POLLUTANTS, CHEMICAL;

MUS; RATTUS;

EID: 70449135026     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408440903222177     Document Type: Review

References (141)

1. Alexander DD, Kelsh MA, Mink PJ, Mandel JH, Basu R, Weingart M (2007). A meta-analysis of occupational trichloroethylene exposure and liver cancer. Int Arch Occup Environ Health 81:127-143.
2. Andersen ME (1981). A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: Analysis at steady state. Toxicol Appl Pharmacol 60:509-526.
3. Andersen ME (2003). Toxicokinetic modeling and it's applications in chemical risk assessment. Toxicol Lett 138:9-27.
4. ATSDR (1997). Toxicological Profle for Trichloroethylene (Updated). Atlanta: Agency for Toxic Substances Disease Registry.
5. Baake B, Stewart PA, Waters MA (2007). Uses of and exposure to trichloroethylene in US industry: A systemic literature review. J Occup Environ Hyg 4:375-390.
6. Beland FA, Poirier MC (1993). Signifcance of DNA adduct studies in animals for cancer molecular dosimetry and risk assessment. Environ Health Perspect 99:5-10.
7. Bloemen LJ, Monster AC, Kezic S, Commandeur JN, Veulemans H, Vermeulen NP, Wilmer JW (2001). Study on the cytochrome P-450-and glutathione-dependent biotransformation of trichloroethylene in humans. Int Arch Occup Environ Health 74:102-108.
8. Bogen KT (1988). Pharmacokinetics for regulatory risk analysis: Te case for trichloroethylene. Regul Toxicol Pharmacol 8:447-466.
9. Bogen KT, Gold LS (1997). Trichloroethylene cancer risk; Simplifed calculation of PBPK-based MCLs for cytotoxic end points. Regul Toxicol Pharmacol 25:26-42.
10. Brauch H, Weirich G, Hornauer MA, Storkel S, Wohl T, Bruning T (1999). Trichloroethylene exposure and specifc somatic mutations in patients with renal cell carcinoma. J Natl Cancer Inst 91:854-861.
11. Brauch H, Weirich G, Klein B, Rabstein S, Bolt HM, Bruning T (2004). VHL mutations In renal cell cancer:Does occupational exposure to trichloroethylene make a diference? Toxicol Lett 151:301-310.
12. Bronley-DeLancey A, McMillan DC, McMillan JM. Jollow DJ, Mohr LC, Hoel DG (2006). Application of cryopreserved human hepatocytes in trichloroethylene risk assessment: Relative disposition of chloral hydrate to trichloroacetate and trichloroethanol. Environ Health Perspect 114:1237-1242.
13. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997). Physiological parameter values for physiologically based pharmacokinetic modeling. Toxicol Ind Health 13:407-484.
14. Bruckner JV, Ramanathan R, Lee KM, Muralidhara S (2002). Mechanisms of circadian rhythmicity of carbon tetrachloride hepatotoxicity. J Pharmacol Exp Terap 300:273-281.
15. Bruning T, Bolt HM (2000). Renal toxicity and carcinogenicity of trichloroethylene: Key results, mechanisms and controversies. Crit Rev Toxicol 30:253-285.
16. Bull RJ (2000). Mode of action of liver tumor induction by trichloroethylene and its metabolites trichloroactetate and dichloroacetate. Environ Health Perspect 108(Suppl 2):241-259.
17. Bull RJ, Orner GA, Cheng RS, Stillwell L, Stauber AJ, Sasser LB, Lingohr MK, Trall BD (2002). Contribution of dichloroacetate and trichloroacetate to liver tumor induction in mice by trichloroethylene. Toxicol Appl Pharmacol 182:55-65.
18. Butterworth BE, Templin MV, Borghof SJ, Conolly RB, Kedderis GL, Wolf DC (1995). Te role of regenerative cell proliferation in chloroform-induced cancer. Toxicol Lett 82/83:23-25.
19. Caldwell JC, Keshava N (2006). Key issues in the modes of action and efects of trichloroethylene metabolites for liver and kidney tumorigenesis. Environ Health Perspect 114:1457-1463.
20. Caldwell JC, Evans ME, Marcus AH, Scott CS, Chiu WA, Okino MS, Preuss PW (2006). Comments on article "Applying mode-of-action and pharmacokinetic considerations in contemporary risk assessments: An example with trichloroethylene" by Clewell and Andersen. Crit Rev Toxicol 36:291-294.
21. Cattley RC (2003). Regulation of cell proliferation and cell death by peroxisome proliferators. Microscopy Res Tech 61:179-184.
22. Cattley RC, DeLuca J, Elcombe C, Fenner-Crisp P, Lake BG, Marsman DS, Pastoor TA, Popp JA, Robinson DE, Schwetz B, Tugwood J, Wahli W (1998). Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol 27:47-60.
23. Charbotel B, Gad S, Caiola D, Beroud C, Fevotte J, Bergeret A, Ferlicot S, Richard S (2007). Trichloroethylene exposure and somatic mutations of the VHL gene in patients with renal cell carcinoma. J Occup Med Toxicol 2:13-20.
24. Chiu WA, Okino MS, Lipscomb JC, Evans MV (2006). Issues in the pharmacokinetics of trichloroethylene and its metabolites. Environ Health Perspect 114:1450-1456.
25. Clewell HJ, Andersen ME (2004). Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: An example with trichloroethylene. Crit Rev Toxicol 34:384-445.
26. Clewell HJ, III, Gentry PR, Covington TR, Gearhart JM (2000). Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ Health Perspect 108(Suppl 2):283-305.
27. Cofn JC, Ge R, Yang S, Kramer PM, Tao L, Pereira MA (2000). Efect of trihalomethanes on cell proliferation and DNA methylation in female B6C3F1 mouse liver. Toxicol Sci 58:243-252.
28. Cook JC, Klinefelter GR, Hardisty JF, Sharpe RM, Foster PMD (1999). Rodent Leydig cell tumorigenesis: A review of the physiology, pathology, mechanisms and relevance to humans. Crit Rev Toxicol 29:169-261.
29. Corton JC, Lapinskas PJ, Gonzalez FJ (2000). Central role of PPARa in the mechanism of action of hepatocarcinogenic peroxisomal proliferators. Mutat Res 448:139-151.
30. Cotruvo JA (1988). Drinking water standards and risk assessment. Regul Toxicol Pharmacol 8:288-299.
31. Coussens LM, Werb Z (2002). Infammation and cancer. Nature 420:860-867.
32. Covington TR, Clewell HJ, Fisher JW (2006). Development of a physiologically-based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Wright-Patterson AFB, OH: Human Efectiveness Directorate Biosciences and Protection Division. AFRL-HE-WP-TR-2006-10049 Available at stinet.dtic.mil.
33. DeAngelo AB, Daniel FB, Most BM, Olson GR (1996). Te carcinogenicity of dichloroacetic acid in the male Fischer 344 rat. Toxicology 114:207-221.
34. Dekant W (2001). Does exposure to trichloroethylene in low doses constitute a cancer risk to humans? Human Ecol Risk Assess 7:657-675. (Pubitemid 33817421)
35. DuTeaux SB, Hengel MJ, DeGroot DE, Jelks KA and Miller MG (2003). Evidence for trichloroethylene bioactivation and adduct formation in the rat epididymis and eferent ducts. Biol Reprod 69:771-779.
36. Fay RM, Mumtaz MM (1996). Development of a priority list of chemical mixtures occurring at 1188 hazardous waste sites using the HazDat database. Food Chem Toxicol 34:1163-1165.
37. Fisher JW (2000). Physiologically based pharmacokinetic models for trichloroethylene and its oxidative metabolites. Environ Health Perspect 108(Suppl 2):265-273.
38. Fisher JW, Mahle D, Abbas R (1998). A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites trichloroacetic acid and free trichloroethanol. Toxicol Appl Pharmacol 152:339-359.
39. Folland DS, Schafner W, Ginn EH, Croford OB, McMurray DR (1976). Carbon tetrachloride toxicity potentiated by isopropyl alcohol. JAMA 236:1853-1856.
40. Forkert P-G, Baldwin RM, Millen B, Lash LH, Put DA, Shultz MA, Collins KS (2005). Pulmonary bioactivation of trichloroethylene to chloral hydrate: Relative contributions of CYP2E1, CYP2F and CYP2B1. Drug Metab Dispos 33:1429-1437.
41. Forkert P-G, Lash LH, Nadeau V, Tardif R, Simmonds A (2002). Metabolism and toxicity of trichloroethylene in epididymis and testes. Toxicol Appl Pharmacol 182:244-254.
42. Forkert P-G, Lash L, Tardif R, Tanphaichitr N, Vandevoort C, Moussa M (2003). Identifcation of trichloroethylene and its metabolites in human seminal fuid of workers exposed to trichloroethylene. Drug Metab Dispos 31:306-311.
43. Gargas ML, Burgess RJ, Voisard DE, Cason GH, Andersen ME (1989). Partition coefcients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicol Appl Pharmacol 98:81-99.
44. Ge R, Pang W, Kramer PM, Yang S, Tao L, Pereira MA (2001). Wy-14643-induced hypomethylation of the c-myc gene in mouse liver. Toxicol Sci 62:28-35.
45. Golden RJ, Holm SE, Robinson DE, Julkunen PH, Reese EA (1997). Chloroform mode of action: Implications for cancer risk assessment. Regul Toxicol Pharmacol 26:142-155.
46. Gonzalez FJ, Shah YM (2008). PPARα: Mechanism of species diferences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246:2-8.
47. Gordon SM, Brinkman MC, Ashley DL, Blount BC, Lyu C, Masters J, Singer PC (2006). Changes in breath trihalomethane levels resulting from household water-use activities. Environ Health Perspect 114:514-521.
48. Green T (2000). Pulmonary toxicity and carcinogenicity of trichloroethylene. Species diferences and modes of action. Environ Health Perspect 108(Suppl 2):261-264.
49. Green T, Dow J, Ellis MK, Odum J (1997). Te role of glutathione conjugation in the development of kidney tumors exposed to trichloroethylene. Chem-Biol Interact 105:99-117.
50. Guengerich FP, Kim DH, Iwasaki M (1991). Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4:168-179.
51. Hack CE, Chiu WA, Zhao QJ, Clewell HJ (2006). Bayesian population analysis of a harmonized physiologically-based pharmacokinetic model of trichloroethylene and its metabolites. Regul Toxicol Pharmacol 46:63-83.
52. Halmes NC, McMillan DC, Oatis, JE, Jr, Pumford NR (1996). Immunochemical detection of protein adducts in mice treated with trichloroethylene. Chem Res Toxicol 9:451-456.
53. Hard GC, Boorman GA, Wolf DC (2000). Re-evaluation of the 2-year chloroform drinking water carcinogenicity bioassay in Osborne-Mendel rats supports chronic renal tubule injury as the mode of action underlying the renal tumor response. Toxicol Sci 53:237-244.
54. Hart RW, Frame L (1996). Toxicologic defense mechanisms and how they afect the nature of the dose-response relationships. BELLE Newslett 5:1-25.
55. Haselkorn T, Whittemore, AS, Udaltsova N, Friedman, GD (2006). Short-term chloral hydrate administration and cancer in humans. Drug Safety 29:67-77.
56. Haseman JK, Hailey JR, Morris RW (1998). Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: A National Toxicology Program update. Toxicol Pathol 26:428-441.
57. Henderson GN, Yan Z, James MO, Davydova N, Stacpoole PW (1997). Kinetics and metabolism of chloral hydrate in children: Identifcation of dichloroacetate as a metabolite. Biochem Biophys Res Commun 235:695-698.
58. Henschler D, Hoos WR, Fetz H, Dollmeier E, Metzler M (1980). Reactions of trichloroethylene by long-term inhalation in three animal species. Arch Toxicol 43:237-248.
59. Henschler D, Vamvakas S, Lammert M, Dekant W, Kraus B, Tomas B, Ulm K (1995). Increased incidence of renal cell tumors in a cohort of cardboard workers exposed to trichloroethylene. Arch Toxicol 69:291-299
60. IARC (1995). Dry Cleaning, Some Chlorinated Solvents and Other Industrial Chemicals. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Vol 63. Lyon, France: IARC.
61. IOM (2003). Gulf War and Health. Vol 2. Insecticides and Solvents. Institute of Medicine. Washington DC: National Academies Press.
62. Ito Y, Yamanoshita O, Asaeda N, Tagawa Y, Lee C, Aoyama T, Ichihara G, Furuhashi K, Kamijima M, Gonzalez FJ, Nakajima T (2007). Di(2-ethylhexly) phthalate induces hepatic tumors through a peroxisomal proliferator-activated receptor-independent pathway. J Occup Health 49:172-182.
63. Jerina DM, Chadha A, Cheh AM, Schurdak ME, Wood AW, Sayer JM (1990). Covalent bonding of bay-region diol epoxides to nucleic acids. Adv Exp Med Biol 283:533-555.
64. Kadlubar FF, Talaska G, Lang NP, Benson RW, Roberts DW (1988). Assessment of exposure and susceptibility to aromatic amine carcinogens. IARC Scientifc Publ 89:166-174.
65. Kaneko T, Wang PY, Sato A (1994). Enzymes induced by ethanol diferently afect the pharmacokinetics of trichloroethylene and 111-trichloroethane. Occup Environ Med 51:113-119.
66. Kedderis GL (1997). Extrapolation of in vitro enzyme induction data to humans in vivo. Chem-Biol Interact 107:109-121.
67. Keengwe IN, Hedge S, Dearlove O, Yates RW, Sharples A (1999). Structured sedation program for magnetic resonance imaging examination in children. Anesthesia 54:1069-1072.
68. King-Herbert A, Tayer K (2006). NTP workshop: Animal models for the NTP rodent cancer bioassay: Stocks and strains-should we switch? Toxicol Pathol 34:802-805.
69. Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM, Roberts RA, Fenner-Crisp PA (2003). PPAR alpha agonist-induced rodent tumors: Modes of action and human relevance. Crit Rev Toxicol 33:655-780.
70. Kundu JK, Surh YJ (2008). Infammation: Gearing the journey to cancer. Mutat Res 659:15-30.
71. Lamb JC, Hentz KL (2006). Toxicological review of male reproductive efects and trichloroethylene exposure: Assessing the relevance to human male reproductive health. Reprod Toxicol 22:557-563.
72. Lash LH, Fisher JW, Lipscomb JC, Parker JC (2000a). Metabolism of trichloroethylene. Environ Health Perspect 108(Suppl 2):177-200.
73. Lash LH, Parker JC, Scott CS (2000b). Modes of action of trichloroethylene for kidney tumorigenesis. Environ Health Perspect 108(Suppl 2):225-240.
74. Lash LH, Qian W, Putt DA, Hueni SE, Elfarra AA, Krause RJ, Parker JC (2001). Renal and hepatic toxicity of trichloroethylene and glutathione-derived metabolites in rats and mice: Sex-, species-, and tissue-dependent diferences. Toxicol Appl Pharmacol 179:163-171.
75. Latendresse JR, Pereira MA (1997). Dissimilar characteristics of N-methyl-N-nitrosourea-initiated foci and tumors promoted by dichloroacetic acid or trichloroacetic acid in the liver of female B6C3F1 mice. Toxicol Pathol 25:433-440.
76. Laughter AR, Dunn CS, Swanson CL, Howroyd P, Cattley RC, Corton JC (2004). Role of the peroxisomal proliferators-activated receptor α (PPRAα) in responses to trichloroethylene and metabolites trichloroacetate and dichloracetetate in mouse liver. Toxicology 203:83-98.
77. Lavin AL, Jacobson CF, DeSesso JM (2000). An assessment of the carcinogenic potential of trichloroethylene in humans. Human Ecol Risk Assess 6:575-641.
78. Lee KM, Bruckner JV, Muralidhara S, Gallo JM (1996). Characterization of presystemic elimination of trichloroethylene and its nonlinear kinetics in rats. Toxicol Appl Pharmacol 139:262-271.
79. Lee KM, Muralidhara S, White CA, Bruckner JV (2000). Mechanisms of the dose-dependent kinetics of trichloroethylene. Oral bolus dosing of rats. Toxicol Appl Pharmacol 164:55-64.
80. Lee LJ, Chung CW, Ma YC, Wang GS, Chen PC, Hwayn YH, Wang JD (2003). Increased mortality odds ratio of male liver cancer in a community contaminated by chlorinated hydrocarbons in groundwater. Occup Environ Med 60:364-369.
81. Li T, Schultz I, Keys, UA, Campbell JL, Fisher JW (2008). Quantitative evaluation of dichloroacetic acid kinetics in human-A physiologically based pharmacokinetic modeling investigation. Toxicology 245:35-48.
82. Lipscomb JC, Teuschler LK, Swartout J, Popken D, Cox T, Kedderis GL (2003). Te impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans. Risk Anal 23:1221-1238.
83. Lipworth L, Tarone RE, McLaughlin JK (2006). Te epidemiology of renal cell carcinoma. J Urol 176:2353-2358.
84. Liu Y, Bartlett MG, White CA, Muralidhara S, Bruckner JV (2009). Characterization of presystemic elimination of trichloroethylene (TCE) in rats following environmentally relevant exposures. Drug Metab Dispos 37:1-5.
85. Liu Y, Muralidhara S, Bruckner JV, Bartlett MG (2008). Determination of trichloroethylene in biological samples by headspace solid-phase microextraction gas chromatography/mass spectrophotometery. J Chromatogr B 863:26-35.
86. Lock EA, Reed CJ (2006). Trichloroethylene: Mechanisms of renal toxicity and renal cancer and relevance to risk assessment. Toxicol Sci 91:313-331.
87. Luch A (2002). Cell cycle control and cell division: Implications for chemically induced carcinogenesis. Chembiochem 3:506-516.
88. Lumpkin MH, Bruckner JV, Campbell JL, Dallas CE, White, CA, Fisher JW (2003a). Plasma binding of trichloroacetic acid in mice, rats and humans under cancer bioassay and environmental exposure conditions. Drug Metab Dispos 31:1203-1207.
89. Lumpkin MH, Dallas CE, Bruckner JV, Fisher JW (2003b). Physiologically based pharmacokinetic modeling of species-specifc efects of plasma binding of trichloroacetic acid from trichloroethylene in mice, rats and humans. Toxicologist 72:178.
90. Magee PN, Barnes JM (1967). Carcinogenic nitroso compounds. Adv Cancer Res 10:163-246.
91. Mally A, Walker CL, Everitt JI, Dekant W, Vamvakas S (2006). Analysis of renal cell transformation following exposure to trichloroethene in vivo and its metabolite S-(dichlorovinyl)-l-cysteine in vitro. Toxicology 22:108-118.
92. Maltoni C, Lefemine G, Cotti G, Perino G (1988). Long-term carcinogenicity bioassays on trichloroethylene administered by inhalation to Sprague-Dawley rats and Swiss and B6C3F1 mice. Ann N Y Acad Sci 534:316-342. (Pubitemid 18205928)
93. Manno M, Rezzadore M, Grossi M, Sbrana C (1996). Potentiation of occupational carbon tetrachloride toxicity by ethanol abuse. Hum Exp Toxicol 15:294-300.
94. Merdink JL, Robison LM, Stevens DK, Hu M, Parker JC, Bull RJ (2008). Kinetics of chloral hydrate and its metabolites in male human volunteers. Toxicology 245:130-140.
95. Miller JA, Miller EC (1977). Te concept of reactive electrophilic metabolites in chemical carcinogenesis: Recent results with aromatic amines safrole and afatoxin B1. In: Jollow D, Kocsis J, Snyder R, Vainio H, eds. Biological Reactive Metabolites: Formation Toxicity and Inactivation. New York: Plenum Press, 6-24.
96. Moran MJ, Zogorski JS, Squillace PJ (2007). Chlorinated solvents in groundwater of the United States. Environ Sci Technol 41:74-81.
97. Morimura K, Cheung C, Ward JM, Reddy JK, Gonzalez FJ (2006). Diferential susceptibility of mice humanized for peroxisome proliferator-activated receptor (alpha) to Wy-14643-induced liver tumorigenesis. Carcinogenesis 27:1074-1080.
98. Nakabeppu Y, Tsuchimoto D, Furuichi M, Sakumi K (2004). Te defense mechanisms in mammalian cells against oxidative damage in nucleic acids and their involvement in the suppression of mutagenesis and cell death. Free Radic Res 38:423-429.
99. Nakajima T, Okino T, Okuyama S, Kaneko T, Yonekura L, Sato A (1988). Ethanol-induced enhancement of trichloroethylene metabolism and hepatotoxicity: Diference from the efect of phenobarbital. Toxicol Applied Pharmacol 94:227-237.
100. NRC (National Research Council). (2006). Assessing the Human Health Risks of Trichloroethylene. Key Scientifc Issues. Washington, DC: National Academies Press
101. NRC (National Research Council). (2009). Contaminated Water Supplies at Camp Lejeune-Assessing Potential Health Efects. Washington, DC: National Academies Press.
102. NTP (2000a). National Toxicology Program Toxicological and Carcinogenesis Studies of Chloral Hydrate (Ad Libitum and Feed Restricted) in B6C3F1 Mice (Gavage Studies). NTP TR 503. NIH Publ. No.00-4437.
103. NTP (2000b). National Toxicology Program Toxicology and Carcinogenesis Studies of Chloral Hydrate in B6C3F1 Mice (Gavage Study). NTP TR 502. NIH Publ. No.00-4436.
104. NTP (1988). National Toxicology Program Toxicology and Carcinogenesis Studies of Trichloroethylene in Four Strains of Rats (ACI, August, Marshall, Osborne-Mendel). (Gavage Studies). NTP TR 273.
105. Odum J, Foster JR, Green T (1992). A mechanism for the development of Clara cell lesions in the mouse lung after exposure to trichloroethylene. Chem-Biol Interact 83:135-153.
106. Pereira MA, Phillips JB (1996). Promotion by dichloroacetic acid and trichloroacetic acid of N-methyl-N-nitrosourea cancer in the liver of female B6C3F1 mice. Cancer Lett 102:133-141.
107. Preussmann R (1984). Carcinogenic N-nitroso compounds and their environmental signifcance. Naturwissenschaften 71:25-30.
108. Price PS, Conolly R, Chaisson CF, Grass EA, Young JS, Mathis ET, Tedder DR (2003). Modeling inter-individual variation in physiological factors in PBPK models of humans. Crit Rev Toxicol 33:469-503.
109. Raaschou-Nielsen O, Hansen J, McLauglin JK, Kolstad H, Christensen JM, Tarone RE, Olsen JH (2003). Cancer risk among workers at Danish companies using trichloroethylene: A cohort study. Am J Epidemiol 148:1182-1192.
110. Rozalski R, Gackowski D, Roszkowski K, Foksinski M, Olinski R (2002). Te level of 8-hydroxyguanine, an apparent repair product of oxidative DNA damage is higher in urine of cancer patients than in control subjects. Cancer Epidemiol Biomark Prevent 11:1072-1075.
111. Saghir SA, Shultz IR (2002). Low-dose pharmacokinetics and oral bioavail-ability of dichloroacetate in naïve and GST-zeta-depleted rats. Environ Health Perspect 110:757-763.
112. Sawant SP, Dnyanmote AV, Shankar K, Limaye PB, Latendresse JR, Mehendale HM (2004). Potentiation of carbon tetrachloride hepatotoxicity and lethality in Type 2 diabetic rats. J Pharmacol Exp Ter 308:694-704.
113. Schultz IR, Merdink JL, Gonzalez-Leon A, Bull RJ (1999). Comparative toxicokinetics of chlorinated and brominated haloacetates in F344 rats. Toxicol Appl Pharmacol 158:103-114.
114. Scott CS, Chiu WA (2006). Trichloroethylene cancer epidemiology: A consideration of selected issues. Environ Health Perspect 114:1471-1478.
115. Stacpoole PW, Gilbert LR, Neiberger RE, Carney PR, Valenstein E, Teiraque DW, Shuster JJ (2008). Evaluation of long-term treatment of children with congenital lactic acidosis. Pediatrics 121:1223-1228.
116. Steinberg AD (1993). Should chloral hydrate be banned? Pediatrics 92:442-446.
117. Stenner RD, Merdink JL, Stevens DK, Springer DL, Bull RJ (1997). Enterohepatic recirculation of trichloroethanol glucuronide as a signifcant source of trichloroacetic acid. Metabolites of trichloroethylene. Drug Metab Dispos 25:529-535.
118. Sung TI, Chen PC, Lee L J-H, YP, Hsieh GY, Wang JD (2007). Increased standardized incidence ratio of breast cancer in female electronics workers. BMC Public Health 7:102-108.
119. Tallarida RJ, Jacob LS (1975). Te Dose-Response Relation in Pharmacology. New York: Springer-Verlag.
120. Tao L, Ge R, Xie M, Kramer PM, Pereira MA (1999). Efect of trichloroethylene on DNA methylation and expression of early-intermediate protooncogenes in the liver of B6C3F1 mice. J Biochem Mol Toxicol 13:231-237.
121. Tao L, Kramer PM, Ge R, Pereira MA (1998). Efect of dichloroacetic acid and trichloroacetic acid on DNA methylation in liver and tumors of female B6C3F1 mice. Toxicol Sci 43:139-144.
122. Tao L, Li Y, Kramer PM, Wang W, Pereira MA (2004). Hypomethylation of DNA and the insulin-like growth factor-II gene in dichloroacetic-and trichloroacetic acid-promoted mouse liver tumors. Toxicology 196:127-136.
123. Tao L, Yang S, Xie M, Kramer PM, Pereira MA (2000). Efect of trichloroethylene metabolites dichloroacetic acid and trichloroacetic acid on the methylation and expression of c-jun and c-myc protooncogenes in mouse liver: Prevention with methionine. Toxicol Sci 54:399-407.
124. Tong Z, Board PG, Anders MW (1998). Glutathione transferase zeta catalyzes the oxygenation of the carcinogen dichloroacetic acid to glyoxylic acid. Biochem J 331:371-374.
125. Tugwood JD, Aldridge TC, Lambe KG, MacDonald N, Woodyat NJ (1997). Peroxisome proliferator activated-receptor: Structures and functions. Ann N Y Acad Sci 804:252-265.
126. USEPA (2000). Toxicological Review of Chloral Hydrate: In support of Summary Information on the Integrated Risk Information System (IRIS). EPA/635/R-00/006. Washington, DC: US Environmental Protection Agency
127. USEPA (2001). Trichloroethylene Health Risk Assessment: Synthesis and Characterization: External Review Draft. EPA/600/P-01/002A. Washington, DC: Ofce of Research and Development, US Environmental Protection Agency.
128. USEPA (2005). Guidelines for Carcinogen Risk Assessment. EPA/630/P-03/001F. Washington DC: US Environmental Protection Agency, Risk Assessment Forum.
129. Vade A, Sukhani R, Dolenga M, Habisohn-Schuck C (1995). Chloral hydrate sedation of children undergoing CT and MR imaging: Safety as judged by American Academy of Pediatrics Guidelines. Am J Roentgenol 165:905-909.
130. Vamvakas S, Bruning T, Tomasson B, Lammert M, Baumuller A, Bolt HM, Dekant W, Birmer G, Henschler D, Ulm K (1998). Renal cell cancer correlated with occupational exposure to trichloroethylene. J Cancer Res Clin Oncol 124:374-382.
131. Volkel W, Friedewald M, Lederer E, Pahler A, Dekant W (1998). Biotrans-formation of perchloroethylene: Dose-dependent excretion of trichloracetic acid, dichloroacetic acid and N-acetyl-S-(trichlorovinyl)-l- cysteine in rats and humans after inhalation. Toxicol Appl Pharmacol 153:20-27.
132. Waddell WJ (2003). Tresholds of carcinogenicity in the ED01 study. Toxicol Sci 72:158-163.
133. Walgren JE, Kurtz DT, McMillan JM (2000a). Te efect of trichloroethylene metabolites trichloroacetate and dichloroacetate on peroxisome proliferation and DNA synthesis in cultured human hepatoctes. Cell Biol Toxicol 16:257-273.
134. Walgren JE, Kurtz DT, McMillan JM (2000b). Expression of PPARα in human hepatocytes and activation by trichloroacetate and dichloroacetate. Res Commun Mol Pathol Pharmacol 108:116-132.
135. Walgren JL, Kurtz DT, McMillan JM (2005). Lack of direct mutagenic activity of dichloroacetate and trichloroacetate in cultured rat hepatocytes. Toxicology 211:220-230.
136. Wartenberg D, Reyner D, Scott CS (2000). Trichloroethylene and cancer: Epidemiologic evidence. Environ Health Perspect 108(Suppl 2): 161-176.
137. Weisel CP, Jo WK (1996). Ingestion, inhalation, and dermal exposures to chloroform and trichloroethene from tap water. Environ Health Perspect 104:48-51.
138. Xu H, Tanphaichitr N, Forkert P-G, Anupriwan A, Weerachatyanukul W, Vincent R, Leader A, Wade MG (2004). Exposure to trichloroethylene and its metabolites causes impairment of sperm fertilizing ability in mice. Toxicol Sci 82:590-597.
139. Yang J, Yu Y, Hamrick HE, Duerksen-Hughes PJ (2003). ATM, ATR and DNA-PK: Initiators of the cellular genotoxic stress responses. Carcinogenesis 24:1571-1580. (Pubitemid 37304662)
140. Yang Q, Nagano T, Shah Y, Cheung C, Ito S, Gonzalez FJ (2008). Te PPARa-humanized mouse: A model to investigate species diferences in liver toxicity mediated by PPARa. Toxicol Sci 101:132-139.
141. Zhao Y, Krishnadasan A, Kennedy N, Morgenstern H, Ritz B (2005). Estimated efects of solvents and mineral oils on cancer incidence and mortality in a cohort of aerospace workers. Am J Ind Med 48:249-256.